FDA Determines Regulatory Review Period for ZACTRAN Patent Extension

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for ZACTRAN, a patent extension application submitted to the Director of Patents and Trademarks, Department of Commerce, for an animal drug product. The FDA is publishing this notice as required by law.